Abstract:Yiming Zhou, 1 Rui Chai, 2 Yongxiang Wang, 3 Xiaojun Yu 3 1 Department of Hepatopancreatobiliary Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, People's Republic of China; 2 General Surgery, Cancer Center, Department of Colorectal Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, People's Republic of China; 3 Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, People's Republic of China Correspondence: Xiaojun Yu, Email Background: EIF3D, a key component of the eukaryotic translation initiation factor 3 (EIF3) complex, is critical in selectively translating mRNAs with atypical cap structures. Its relationship with colon adenocarcinoma (COAD) development and immune infiltration, however, remains under-explored. This study delves into EIF3D's role in COAD using bioinformatics and in vitro experimentation. Materials and Methods: We analyzed EIF3D expression levels utilizing TCGA, GTEx, CPTAC, and TISIDB databases. The TISCH database and ssGSEA method helped in assessing EIF3D's link with the tumor immune microenvironment. EIF3D expression in CRC cells was gauged via real-time PCR. Cell proliferation was assessed using CCK8 and colony formation assays, while migration capabilities were tested through Transwell assays. Flow cytometry facilitated cell cycle distribution and apoptosis analysis. ChIP-qPCR identified transcription factors regulating EIF3D, and bulk sequencing explored EIF3D's pathways in promoting COAD. Results: EIF3D upregulation is a common feature in various tumors, especially in COAD, correlating with poor prognosis in many cancer types. It showed significant associations with immune cell and cancer-associated fibroblast (CAF) infiltration across multiple tumors. Additionally, it is closely associated with molecular and immune subtypes of multiple tumors, including COAD. Single-cell analyses depicted EIF3D's distribution and proportion in CRC immune cells. In vitro findings indicated EIF3D knockdown curtailed proliferation and migration, inducing G0/G1 arrest in COAD cells. Moreover, bulk sequencing revealed EIF3D knockdown interferes with multiple cancer-related pathways, likely by curtailing cell cycle and DNA replication activities to regulate cell proliferation. Conclusion: EIF3D emerges as a potential prognostic biomarker for tumor progression and immune infiltration, particularly in COAD, potentially predicting immunotherapy efficacy. Additionally, EIF3D represents a multifaceted target implicated in COAD's malignant progression. Keywords: EIF3D, pan-cancer, tumor immune microenvironment, biomarker, therapeutic target Cancer, recognized as a formidable global health threat, not only contributes to significant incidence and mortality rates but also stands as a major barrier to life extension. 1–3 In the evolving landscape of cancer treatment, we are currently witnessing the emergence of a pan-cancer era. A plethora of cancer treatment modalities have surfaced in recent years, with immunotherapy notably thriving and attracting extensive attention in both academic and clinical realms. 4,5 Immunotherapy functions by intricately orchestrating the human immune system to actively engage in the battle against tumors. 6,7 The tumor immune microenvironment (TIM) is instrumental in the efficacy of immunotherapy. Research underscores that the activity status and distribution of immune and stromal cells within the TIM are critical determinants of patients' prognosis and treatment outcomes. 8,9 Specifically, T cells, especially the CD8+ subset, are frequently associated with a positive prognosis in cancer. 10,11 Conversely, M2-type macrophages and T regulatory cells are widely acknowledged as adverse prognostic factors in cancer. 12–14 Hence, gaining a deeper understanding of and intervening in the TIM is vital for enhancing the effectiveness of treatments. The integration of immunotherapy with conventional modalities such as radiotherapy and chemotherapy, as well as its combination with targeted therapy, has demonstrated synergistic and complementary anti-tumor effects, offering promising prospects for clinical applications. 15,16 Immunotherapeutic strategies, such as immune checkpoint inhibitors (ICIs), have shown significant clinical benefits for a diverse range of cancer patients. 17 However, only a minority of patients experience extended benefits, which necessitates ongoing research and development effo -Abstract Truncated-

Escherichia Coli Adhesion Portion Fimh Functions As An Adjuvant For Cancer Immunotherapy

Escherichia coli adhesion portion FimH polarizes M2 macrophages to M1 macrophages in tumor microenvironment via toll-like receptor 4

Ultrasound Improved Immune Adjuvant Delivery to Induce DC Maturation and T Cell Activation.

Expression of E. coli FimH Enhances Trafficking of an Orally Delivered Lactobacillus acidophilus Vaccine to Immune Inductive Sites via Antigen-Presenting Cells

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Induction of HCA587-Specific Antitumor Immunity with HCA587 Protein Formulated with CpG and ISCOM in Mice

Effect of FAPα-expressing tumor cell vaccine with PD-1 mAb on its efficacy in mice colorectal cancer model.

Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4

Dust mite-derived Enterobacterial fimbriae H protein enforces the allergen specific immunotherapy in asthma mice

Structural basis of adhesin Fap2 interaction with receptors on cancer and immune cells

Fucoidan from Durvillaea Antarctica enhances the anti-cancer effect of anti-PD-L1 antibody by activating dendritic cells and T cells

Deciphering EIF3D's Role in Immune Regulation and Malignant Progression: A Pan-Cancer Analysis with a Focus on Colon Adenocarcinoma

Fes-deficient macrophages enhance CD8+ T cell priming and tumour control through increased proinflammatory cytokine production and presentation

In Vitro Antitumor Immune Response Induced By Fusion Of Dendritic Cells And Colon Cancer Cells

Antibacterial Fusobacterium Nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐colonized Bacteria And Enhance Immunotherapy Against Colorectal Cancer

HCA587/MAGE-C2 protein formulated with CFA and CpG elicits potent immune responses and antitumor effects in mice

Hsp70-Like Protein 1 Fusion Protein Enhances Induction Of Carcinoembryonic Antigen-Specific Cd8(+) Ctl Response By Dendritic Cell Vaccine

Combination of Two Fiber-Mutant Adenovirus Vectors, One Encoding the Chemokine FKN and Another Encoding Cytokine Interleukin 12, Elicits Notably Enhanced Anti-Tumor Responses

Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer

MODULATION OF TUMORICIDAL ACTIVITIES OF DENDRITIC CELLS TO ENHANCE ANTIGEN UPTAKE AND CROSS-PRESENTATION

Cancer immunotherapy using a polysaccharide from Codium fragile in a murine model